Combined Vacuum-assisted Closure Therapy and CACIPLIQ20 for Chronic Wound Management Authors: Reem Saleh Alrajhi, Abdulaziz M. Alghamdi, Eman M. Alshammari, Khalid A. Fayi, Nora Alsaud, Abdulaziz S. Almosa, Abdullah Mohammed Alzahrani, Rosevie Segismundo, Fuad Hashem Published: 2025 ABSTRACT Summary:Chronic wounds, defined as wounds that fail to heal within 12 weeks, pose significant clinical challenges. Management follows the tissue, infection, moisture, and edge principle, which emphasizes tissue debridement, infection control, moisture balance, and wound-edge optimization. This case series examined the use of vacuum-assisted closure (VAC) therapy combined with CACIPLIQ20 (OTR3, Paris, France), a regenerating tissue analog, in 4 patients with chronic or complex wounds. The first case involved a 13-year-old boy with delayed healing and hardware exposure after scoliosis correction surgery, successfully treated with VAC therapy and CACIPLIQ20. The second case described a 77-year-old man with a recurrent malignant peripheral nerve sheath tumor requiring surgical excision and a skin graft, which healed with VAC therapy and CACIPLIQ20. The third case featured a 14-year-old girl who developed vertebral osteomyelitis and a wound infection after kyphosis correction surgery, managed with debridement, VAC therapy, and CACIPLIQ20. The fourth case involved a 55-year-old man with diabetes and a necrotic foot wound requiring below-knee amputation, followed by VAC therapy and CACIPLIQ20, resulting in successful closure. CACIPLIQ20 restores heparan sulfate function, enhances extracellular matrix integrity, and accelerates wound healing. This case series supported the use of VAC therapy and CACIPLIQ20 as a promising approach to chronic wound management. The skin serves as a primary barrier against external insults. Its healing capacity can be compromised by factors such as aging, diabetes, and radiation, potentially resulting in chronic wounds, defined as wounds that fail to heal within 12 weeks.1,2 Management is often guided by the TIME principle: tissue debridement, infection control, moisture balance, and edge advancement. This case series explored the use of vacuum-assisted closure (VAC) therapy combined with regenerating matrix agents (RGTAs) to support wound healing in 4 patients. A hallmark of chronic wounds is the depletion of heparan sulfate (HS), a key extracellular matrix (ECM) component involved in growth factor stabilization and structural integrity. CACIPLIQ20, an engineered RGTA, mimics HS by providing a scaffold for collagen deposition and protecting growth factors from proteolytic degradation. VAC prepares the wound bed, whereas CACIPLIQ20 restores the matrix, together offering a biologically synergistic approach to chronic wound healing.3 CASE PRESENTATIONS Case 1 A 13-year-old boy with a history of repaired myelomeningocele developed delayed wound healing and hardware exposure after scoliosis correction (Fig. 1). He underwent multiple debridements, and computed tomography showed no fluid collections. Due to poor tissue quality, surgical risk, and family preference, conservative management was chosen. VAC therapy with biweekly changes was continued for 4 months, with CACIPLIQ20 (OTR3, Paris, France) added during the final 2 months. Wound dehiscence with exposed spinal hardware following scoliosis correction surgery in case 1. The wound achieved complete coverage with granulation tissue, and the patient was discharged with outpatient follow-up (Fig. 2). Over 6 months of virtual follow-up, the wound remained stable, with no signs of infection or breakdown. The patient reported reduced tenderness, and reepithelialization progressed at the edges. Healed wound with complete spinal hardware coverage following treatment in case 1. Case 2 A 77-year-old man with neurofibromatosis, uncontrolled diabetes, and hypertension presented with a recurrent malignant peripheral nerve sheath tumor in the left gluteal region. After 2 resections and radiation, the tumor recurred in the lower back. Surgical excision was performed, followed by a split-thickness skin graft, which failed (Fig. 3). Given the patient’s poor condition, VAC therapy was used for 4 weeks, with CACIPLIQ20 added in the final 2 weeks to support healing. Surgical defect in the lower back after excision of a recurrent malignant peripheral nerve sheath tumor in case 2. After completing the treatment, the wound was healed completely (Fig. 4). A 4-month follow-up revealed a stable wound with no complications. Healed wound with stable coverage following treatment in case 2. Case 3 A 14-year-old girl with repaired myelomeningocele underwent kyphosis correction with thoracolumbar fusion and developed a postoperative wound infection with drainage and partial dehiscence. Magnetic resonance imaging confirmed osteomyelitis with hardware loosening, and Methicillin-sensitive Staphylococcus aureus was cultured. Due to her condition and the family’s preference, she received debridement, 2 months of VAC therapy, and biweekly CACIPLIQ20 for the final 8 weeks. The wound developed healthy granulation tissue, and she was discharged at her family’s request. One-month follow-up showed no complications. Case 4 A 55-year-old man with HIV, complicated diabetes, status post left below-knee amputation, and dyslipidemia presented with a 5-day history of a necrotic, malodorous right foot wound. Imaging showed bone destruction. After right below-knee amputation, the stump showed delayed healing, requiring 2 months of debridement. The patient declined further surgery, so VAC therapy was used for 4 months, with CACIPLIQ20 added in the final 2 months and a 6-week antibiotic course. The wound formed healthy granulation tissue and healed well with no signs of persistent osteomyelitis. One-month follow-up showed no complications. DISCUSSION Chronic wounds arise from sustained inflammation and impaired tissue repair, often worsened by systemic conditions such as diabetes, obesity, or prior radiation exposure.1,2 The TIME framework remains central to wound care, guiding debridement, infection control, moisture management, and wound-edge optimization.4 When conventional approaches fail, advanced therapies such as VAC and biomimetic agents such as RGTAs can accelerate healing. VAC therapy enhances perfusion, reduces edema, and maintains moisture, helping shorten the inflammatory phase. Yet, chronic wounds are also marked by ECM disruption, especially degradation of HS, a key glycosaminoglycan needed for growth factor stabilization.3 Normally, injury triggers a regulated cascade involving HS degradation to facilitate healing. However, chronic wounds remain trapped in inflammation, with persistent proteolysis degrading growth factors and ECM components, hindering repair.5 CACIPLIQ20 (OTR3), a synthetic RGTA, mimics HS by binding and stabilizing endogenous growth factors and ECM proteins, shielding them from proteolysis while also providing a scaffold for collagen deposition and matrix reconstruction. Its dual action, preserving signaling and supporting structure, is valuable where natural healing is compromised. Used alongside VAC therapy, which prepares the wound bed, CACIPLIQ20 helps restore tissue homeostasis. Alternative agents exist. Regranex (becaplermin), a recombinant PDGF, is Food and Drug Administration–approved treatment for diabetic ulcers and works by stimulating cellular proliferation.6 In contrast, CACIPLIQ20 stabilizes the wound microenvironment and has broader reported uses, including scar modulation.7 Despite these theoretical advantages, most CACIPLIQ20 studies are limited by small sample sizes, lack of controls, and potential bias.1,2,8 Larger trials are needed to assess its true efficacy and cost-effectiveness. Preliminary reports note improved granulation, collagen I/III deposition, and wound closure, often within 8 weeks.2 In our experience, more complex wounds required up to 4 months of VAC therapy, followed by 8 weeks of CACIPLIQ20. Rigorous debridement remained essential, as fibrin may sequester RGTA and reduce efficacy.8 Despite limitations, observed benefits include improved scar outcomes and faster recovery in patients with poor vascular supply, diabetes, or a smoking history.9 One notable case involved a 22-year-old man with Stewart-Bluefarb syndrome who healed completely within 4 weeks of CACIPLIQ20 use.10 This series highlighted the need for further studies to isolate the role of CACIPLIQ20 and compare it directly with agents such as becaplermin. CONCLUSIONS A comprehensive approach to chronic wound management, integrating the TIME principle, debridement, VAC therapy, and CACIPLIQ20, offers a promising strategy for improving healing outcomes, especially in medically complex patients or when surgery is not feasible. In this series, VAC and CACIPLIQ20 consistently supported granulation, reepithelialization, and durable wound closure across diverse clinical settings. VAC prepares the wound bed by enhancing perfusion and reducing inflammation, whereas CACIPLIQ20 restores ECM integrity and preserves growth factors essential for repair. These cases highlight the importance of individualized, multidisciplinary care and the need for further studies to define the role of CACIPLIQ20 in modern wound protocols. DISCLOSURE The authors have no financial interest to declare in relation to the content of this article.